Literature DB >> 7529693

Quantitative EMG in botulinum toxin treatment of cervical dystonia. A double-blind, placebo-controlled study.

L Ostergaard1, A Fuglsang-Frederiksen, L Werdelin, O Sjö, H Winkel.   

Abstract

We used turns-amplitude analysis of the EMG as a guidance for botulinum toxin (BT) treatment in 19 patients with cervical dystonia. At the first examination, muscles showing abnormal activity (> 100 turns/sec at rest) were given BT 75 units (10 patients) or placebo (9 patients). At subsequent examinations, about 6, 12 and 18 weeks after the start, BT 75 units were given to all hyperactive muscles. Six weeks after the first BT treatment the sternocleidomastoid muscle contralateral to the involuntary head rotation and the ipsilateral and contralateral posterior neck muscles (PNM) showed a reduction of involuntary activity, as indicated by reduced turns/sec and mean amplitude at rest. Similar changes were seen when comparing BT treatment with placebo. The reduction was greater in the contralateral sternocleidomastoid muscle than in PNM, suggesting that PNM need higher doses of BT. At maximal voluntary contraction, BT treated muscles showed unchanged turns/sec (5/6 tests), decreased mean amplitude and increased ratio (turns/amplitude). This may reflect a functional random loss of muscle fibres, combined with inability to activate all motor units. A high (89%) clinical success rate with BT therapy was obtained, and it is concluded that quantitative EMG is a useful tool for the precise identification of hyperactive muscles, for optimal placing of the injection cannula and for unbiased monitoring of the treatment effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529693     DOI: 10.1016/0168-5597(94)90150-3

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  7 in total

Review 1.  Botulinum toxin type A therapy for cervical dystonia.

Authors:  Mafalda Castelão; Raquel E Marques; Gonçalo S Duarte; Filipe B Rodrigues; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2017-12-12

Review 2.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Comparison between (18)F-FDG PET/CT and EMG Mapping for Identifying Dystonic Superficial Muscles in Primary Cervical Dystonia: Preliminary Results.

Authors:  Su Jin Jang; Joon Young Choi; Duk Hyun Sung; Kwang Hong Park; Ji Young Lee; Sook Kyung Cho; Jang Yu; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

4.  Botulinum toxin type A therapy for cervical dystonia.

Authors:  Filipe B Rodrigues; Gonçalo S Duarte; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-12

Review 5.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

6.  Proteomic changes in rat gastrocnemius muscle after botulinum toxin a injection.

Authors:  Nami Han; Hyun Dong Kim; Mi-Ja Eom; Jun Myeong You; Jin Han; Hyoung Kyu Kim; Mi Seon Kang
Journal:  Ann Rehabil Med       Date:  2013-04-30

7.  Jitter Evaluation in Distant and Adjacent Muscles after Botulinum Neurotoxin Type A Injection in 78 Cases.

Authors:  Joao Aris Kouyoumdjian; Carla Renata Graça; Fabio Nazare Oliveira
Journal:  Toxins (Basel)       Date:  2020-08-27       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.